{'fraction_non_alphanumeric': 0.04076086956521739, 'fraction_numerical': 0.009963768115942028, 'mean_word_length': 6.269736842105263, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Randomized double-blind study of therapy of sudden deafness: initial results].

Three treatment groups (hydroxyethyl starch-pentoxifylline (HAES-steril/Trental), hydroxyethyl starch-pentoxifylline-naftidrofuryl (HAES-steril/Trental/Dusodril) and dextran-pentoxifylline (Rheomacrodex/Trental] and a placebo therapy control group (normal saline) were compared in a prospective randomised study (102 patients) and a retrospective study (292 patients). The trial therapy results were the same in all groups. However all treatments on patients with a haemoglobin greater than 14 g/l result in a significant hearing improvement compared with the placebo. The patient group with systolic blood pressure greater than 130 mm Hg treated with hydroxyethyl starch-pentoxifylline had a significant hearing improvement compared with the placebo, hydroxyethyl starch-pentoxifylline-naftidrofuryl and dextran-pentoxifylline. With increasing systolic blood pressure, patients in the placebo, hydroxyethyl starch-pentoxifylline-naftidrofuryl and dextran-pentoxifylline groups had a statistically significant worse result.